(Peoples Daily Health Client Wang Yuan) According to incomplete statistics from the Peoples Daily Health Client, this week (November 4th-November 8th), a total of 16 investment in the national pharmaceutical health fieldIncidents, which were listed on the NEEQ of genetic technology and Bo Medical.There are 3 financing amounts of more than 100 million yuan. The traceability, Ripchenchuang, and Ningdans new drugs have received over 100 million yuan investment, involving in vitro diagnostic products, dental medical services, stem cell therapy, etc.Related areas.
Biomedicine
Mid-Sheng Source: Complete 150 million yuan B financing, accelerate the clinical and clinical and accelerated pipelines and clinical and clinical and pipelinesCommercialization
On November 8th, Zhongsheng Tude Biotechnology Co., Ltd. announced that it has completed the first round of financing of 150 million yuan in Series.This round of financing was invested by Guangzhous investment, and joint investment in Zhongyuan Investment, Guoju Venture Capital, Hefei Gao Investment, and Junlian Capital of the old shareholders.This round of financing will be mainly used to accelerate the clinical development of a variety of clinical pipelines in the field of IPSC (induction of multi -energy stem cells) cell therapy and commercialization of subsequent products.Haoyue Capital is the exclusive financial advisor to financing this round of financing.
The Shengsheng Source was established in 2016. The national specialized new "Little Giant" enterprise is located in Hefei City, Anhui Province.With clinical transformation, it is committed to developing a wide range of cell therapy products.
Zhengxi Bio: Complete tens of millions of yuan A+round of financing, deepen the layout of the cell drug industry
11On the 6th, Zhejiang Zhengxi Biotechnology Co., Ltd. announced the completion of a new round of tens of millions of yuan in financing.Investment and Investment by Huarui Investment and Huiyu participated in investment.This round of financing will be mainly used for channel construction, new product development registration, production capacity improvement, and daily operations.
Zhengxi Biology focuses on membrane protein antibodies, multiple groups of antibody fields, surrounding fluorescence detection, immunohistochemical testing, and continuous clinical diagnosis and innovative products of multi -group testing. UpstreamReagent raw materials and third -party terminal special inspections.
Ryida Pharmaceutical: Complete the 10 million -level Series A financing, and break through pharmaceutical innovation
November 6 6On the day, Henan Ruida Pharmaceutical Technology Co., Ltd. announced that it has successfully completed the 10 million -level Series A financing in recent days. This round of financing will be mainly used to accelerate the promotion of new drug research and development pipelines and strengthen team building.
Ryda Pharmaceutical Technology was established on November 6, 2014. It is an anti -cancer targeting innovative drug research and developer.By developing the inhibitors of STAT3, the company expects to achieve the effects of inhibiting the growth, metastasis, vascular production, drug resistance, recurrence and immune escape of the tumor.
Ningdan New Pharmaceutical: Complete hundreds of millions of yuan C financing, focusing on the development of new drugs in the central nervous system
On November 5, Nanjing Ningdan New Pharmaceutical Technology Co., Ltd. announced the completion of Her Series C financing of hundreds of millions of yuan.This round of financing was jointly completed by the Nanjing Jiangning High -tech Zone Science and Technology Investment and Huaxing Kangping. The raised funds will be mainly used to accelerate the development and listing process of the companys core pipelines, the construction of independent innovation platforms, and the companys global layout.
Ning Dans new drug is an innovative company focusing on new drug research and development and industrialization in the field of central nervous system disease (CNS).ability.
Zhiyuan Yuanchuang: Get angel round financing, expand the pipeline of AI drug design
November 5On the day, Zhiyaoyuan Creative Medical Technology (Shanghai) Co., Ltd. announced that it has received tens of millions of yuan of angel round financing. This round of financing is invested by Hushu shares.As a large -molecular drug design company with a full life cycle, the funds raised will be used to expand the pipeline of AI drug design, promote the wet experimental verification of existing polypeptide drug design, and help the development of the industry.Smart Medicine Yuanchuang is a medical technology company founded by researchers
Shandong Renrui: Complete 15 million yuan of financing,
Technology Co., Ltd. announced that it was signed with Shandong Capital Capital Management Co., Ltd. and received an equity investment of 15 million yuan.Renrui Bio is a functional cosmetics and medical dressing service provider. It is committed to the development and production of functional cosmetics, high -end medical dressing, new disinfection sterilization products and hotel cleaning and cleaning products.
Rupchenchuang: Complete over 100 million yuan round A financing, layout diabetes stem cell therapy
NovemberOn the 4th, Hangzhou Ripchen Innovation Technology Co., Ltd. announced the completion of exceeding 100 million yuan in Series A financing.This round of financing is followed by China Wind Investment Leading, Beida Pharmaceutical, Lenovo Venture Capital, Hutang Venture Capital, Bei Orange Venture Capital.Financing funds will be used to accelerate the companys research pipeline and clinical trial process.
Rupchen Chuangchuang was established in 2014 and focused on stem cell regeneration medicine.At present, Ripchens cell therapy drug based on human multi -energy stem cell technology has planned multiple pipelines in the treatment of diabetes. Among them, the U.S. IND Dual News in the main line has entered the track.
Medical Device
Baya-A-A-A-A-round financing process, accelerate the development process of specific peptide vaccines
On November 8th, Bai Aoyacker (Shenyang) Biomedical Group Co., Ltd. announced that it has completed the 10 million yuan Pre-A, which has been completed by Liaoning Wici Medical Investment Management Co., Ltd.Rotation financing is used for the "specific puppet peptide vaccine" product research and development pipeline.
Established in 2016, Baya -Australian Tyk Biomedical Group is a national high -tech enterprise focusing on new technologies, new drugs, new products, and industrial transformation in the field of life sciences.
Fertose Technology: Complete nearly 100 million yuan in financing, accelerate the transformation of core technology achievements
November 7, Feioseki Laser Research Center (Guangzhou) Co., Ltd. announced the completion of nearly 100 million yuan in Series A financing.This round of financing was jointly led by Yuanhe Original Point and Taiyi Fund. Nuos Capital, Capital Capital, Guoju Venture Capital participated in this round of financing.
Flying Stuff Technology is a high -tech and "specialized new" enterprise focusing on femtosecond laser technology in clinical diagnosis and treatment and biomedical industrialization applications.
Robber Medical: Get Hangzhou Guoshun Jianheng A+round financing, develop digestive endoscopic surgery robot
On November 6, Shenzhen Luobo Medical Technology Co., Ltd. announced that it has obtained A+round financing from Hangzhou Guoshun Jianheng Entrepreneurship Investment Partnership (Limited Partnership).This round of financing will help the companys digestion of endoscopic robot Endofasters marketing and the development of various innovative medical products and market introduction.
Robberry was established in 2015 and is committed to the technical research of flexible digestive endoscopic robots.
Lena core: Complete tens of millions of yuan A round of financing, Sichuan Zhenghe Xiang Group led a
On November 5th, Suzhou Linaxin Biotechnology Co., Ltd. completed tens of millions of yuan A financing. This round of financing was led by Sichuan Zhenghexiang Group.Trial production in the solid -state nanohole (fourth -generation) genetic detector, registered reports of early screening products, and expand production bases and product market development.
Suzhou Lenitin creatures focus on the independent research and development, intelligent manufacturing, application, and high -incidence of early screening of high -incidence cancer.
Ding Ding Medical: Receive nearly 100 million yuan C round of financing, help ophthalmological equipment
November 5On the day, Zhiding Medical Technology Co., Ltd. announced the completion of nearly a round C financing of nearly 100 million yuan.This round of financing was led by Tai Pu Life Sciences, and Hanyang Capital, Huiding Capital, Mi Fang Capital and Capital Capital followed.
Perseverance of Ding Ding Medical was established in 2015, focusing on professional medical equipment in the field of ophthalmic,
Yuequan Bionic: NearbyRMB 100 million Pre-A financing, focusing on the research and development of bionic humanoid robot products
On November 5, Yuequan Bionic announced that it has recently completed the near-one million yuan Pre-A round of financing.This round of financing was led by the Hongtai Fund, and the Changxing Fund and Zhongguancun Qi Valley Fund followed the investment.The fundraising funds will be mainly used for humanoid robots research and development, the continuous construction of company talents and technical barriers, and the accelerated delivery of commercialization.Inspur Capital is the exclusive financial consultant of this financing.
Yuequan Bionic focuses on the research and development and industrialization of humanoid robots, core components and bionic intelligent equipment, and realizes the entire machine structure, core structure components, power systems, etc.Chain self -study.
Medical Services
Gene Technology: The New Third Board of Gene Technology is listed, and its operating income of 2023 is 1.093 billion yuan
On November 7, the announcement of the national SME stock transfer system announced that the listing application of gene technology (Shanghai) Co., Ltd. was approved and listed on November 8.The announcement shows that the operating income from January to December 2023 was 1.116 billion yuan and 1.093 billion yuan, and net profit was 64.782 million yuan and 54.131 million yuan, respectively.
According to Flush Shun New Third Board information, the main business of gene technology (Shanghai) Co., Ltd. is to provide high school institutions, scientific research institutions, hospitals, and biomedical enterprises to provide life scientific research instruments,Reagents and in vitro diagnostic instruments, reagents and technical services.The companys main products include two categories: life scientific research service products and services and in vitro diagnostic products.
and Bo Medical: The New Third Board is listed on the market, the main dental medical service
The system announcement shows that the listing application of Guangdong and Bo Medical Group Co., Ltd. was approved and listed on November 8.The announcement shows that the operating income from January to December 2023 was 268 million yuan and 303 million yuan from January to December 2023, and net profit was 11.3586 million yuan and 22.194 million yuan, respectively.
Flush Shun New Third Board information shows that the main business of Guangdong and Bo Medical Group Co., Ltd. is dental medical services.Class, oral surgery, oral planting, oral repair, oral orthodontics.
Mibi Technology: Complete PRE-A round financing, micro-current control production chip company
NovemberOn the 5th news, Hangzhou Jimi Technology Co., Ltd., a micro-current-controlled production chip company, announced the completion of the Pre-A round of financing. This round of financing was led by Capital Capital, Jinshajiang United Capital Following Investment, and Kai Cheng Capital served as a financial adviser.This round of financing raised funds will be mainly used for the construction of the illegal agarose ball production base.
Millet Technology is based on micro -current -controlled production chips as the core to continuously expand the universal production platform of microsphere materials to achieve large -scale production of different particle size and functions.Provide stable high -quality products and customized solutions in many areas such as medical raw materials, drug delivery, in vitro testing.
